CN1152674C - 氟代醚组合物和抑制路易斯酸存在下其降解的方法 - Google Patents

氟代醚组合物和抑制路易斯酸存在下其降解的方法 Download PDF

Info

Publication number
CN1152674C
CN1152674C CNB98802053XA CN98802053A CN1152674C CN 1152674 C CN1152674 C CN 1152674C CN B98802053X A CNB98802053X A CN B98802053XA CN 98802053 A CN98802053 A CN 98802053A CN 1152674 C CN1152674 C CN 1152674C
Authority
CN
China
Prior art keywords
sevoflurane
water
degradation
lewis acid
fluoroether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB98802053XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1244797A (zh
Inventor
C
C·比尼尔兹
S·H·常
K·R·克洛马克
S·L·黄
河合俊和
小林真奈美
D·罗弗雷多
R·拉格哈范
˹�峹��
E·R·斯佩彻尔
˹�ض���ϣ
H·A·斯特尔马希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Central Glass Co Ltd
Abbott Laboratories
Original Assignee
Central Glass Co Ltd
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1152674(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Central Glass Co Ltd, Abbott Laboratories filed Critical Central Glass Co Ltd
Publication of CN1244797A publication Critical patent/CN1244797A/zh
Application granted granted Critical
Publication of CN1152674C publication Critical patent/CN1152674C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Steroid Compounds (AREA)
CNB98802053XA 1997-01-27 1998-01-23 氟代醚组合物和抑制路易斯酸存在下其降解的方法 Expired - Lifetime CN1152674C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US08/789,679 1997-01-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100368062A Division CN1321958C (zh) 1997-01-27 1998-01-23 氟代醚组合物和抑制路易斯酸存在下其降解的方法

Publications (2)

Publication Number Publication Date
CN1244797A CN1244797A (zh) 2000-02-16
CN1152674C true CN1152674C (zh) 2004-06-09

Family

ID=25148366

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB98802053XA Expired - Lifetime CN1152674C (zh) 1997-01-27 1998-01-23 氟代醚组合物和抑制路易斯酸存在下其降解的方法
CNB2004100368062A Expired - Lifetime CN1321958C (zh) 1997-01-27 1998-01-23 氟代醚组合物和抑制路易斯酸存在下其降解的方法
CNA2006101016375A Pending CN1899271A (zh) 1997-01-27 1998-01-23 储存七氟烷的方法以及防止七氟烷被路易斯酸降解的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNB2004100368062A Expired - Lifetime CN1321958C (zh) 1997-01-27 1998-01-23 氟代醚组合物和抑制路易斯酸存在下其降解的方法
CNA2006101016375A Pending CN1899271A (zh) 1997-01-27 1998-01-23 储存七氟烷的方法以及防止七氟烷被路易斯酸降解的方法

Country Status (27)

Country Link
US (6) US5990176A (enExample)
EP (2) EP0967975B1 (enExample)
JP (5) JP3183520B2 (enExample)
KR (1) KR100368672B1 (enExample)
CN (3) CN1152674C (enExample)
AR (2) AR011090A1 (enExample)
AT (2) ATE201987T1 (enExample)
AU (1) AU726733B2 (enExample)
BG (2) BG65414B1 (enExample)
BR (1) BR9806996A (enExample)
CA (2) CA2278133C (enExample)
CO (1) CO4920220A1 (enExample)
CZ (1) CZ297092B6 (enExample)
DE (2) DE69800928T2 (enExample)
DK (2) DK1114641T3 (enExample)
ES (2) ES2256104T3 (enExample)
GR (1) GR3036190T3 (enExample)
HU (1) HUP0002101A3 (enExample)
IL (1) IL130150A (enExample)
NO (1) NO993606L (enExample)
NZ (1) NZ335994A (enExample)
PL (1) PL334477A1 (enExample)
PT (2) PT1114641E (enExample)
SK (1) SK284243B6 (enExample)
TR (1) TR199901579T2 (enExample)
WO (1) WO1998032430A1 (enExample)
ZA (1) ZA98418B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
US6162443A (en) * 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
EP1439677B9 (en) 1999-01-08 2007-11-07 Sony Deutschland GmbH Synchronisation symbol structure for an OFDM system
TW523409B (en) 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
EP1663186B1 (en) * 2003-09-10 2007-06-20 Cristália Produtos Químicos Farmacêuticos Ltda. Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
WO2006113636A2 (en) * 2005-04-18 2006-10-26 Minrad Inc. Preparation of sevoflurane with negligible water content
WO2009049460A1 (en) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. New packaging material for sevoflurane
WO2009094459A1 (en) * 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20090275785A1 (en) * 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) * 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
BE1024432B1 (fr) * 2016-11-02 2018-02-19 Central Glass Company, Limited Procédé pour le lavage de récipient de stockage de sévoflurane et procédé pour le stockage de sévoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
ZA98418B (en) 1999-04-20
CA2278133C (en) 2001-06-26
EP0967975A1 (en) 2000-01-05
HUP0002101A3 (en) 2002-03-28
PT1114641E (pt) 2006-05-31
AU5930098A (en) 1998-08-18
KR100368672B1 (ko) 2003-01-24
HK1074434A1 (en) 2005-11-11
NO993606D0 (no) 1999-07-23
CO4920220A1 (es) 2000-05-29
IL130150A0 (en) 2001-03-19
EP0967975B1 (en) 2001-06-13
JP3664648B2 (ja) 2005-06-29
AR011090A1 (es) 2000-08-02
CZ297092B6 (cs) 2006-09-13
DE69800928D1 (de) 2001-07-19
NO993606L (no) 1999-09-24
SK86199A3 (en) 2000-06-12
CA2278133A1 (en) 1998-07-30
NZ335994A (en) 2000-08-25
EP1114641B1 (en) 2006-03-22
CZ256199A3 (cs) 1999-11-17
US20030130359A1 (en) 2003-07-10
BG65414B1 (bg) 2008-07-31
US20020016373A1 (en) 2002-02-07
JP3183520B2 (ja) 2001-07-09
GR3036190T3 (en) 2001-10-31
US6288127B1 (en) 2001-09-11
DE69833884D1 (de) 2006-05-11
HUP0002101A2 (hu) 2001-05-28
JP2000510159A (ja) 2000-08-08
JP2006143742A (ja) 2006-06-08
DE69800928T2 (de) 2001-11-22
ATE201987T1 (de) 2001-06-15
BG109751A (bg) 2008-06-30
BG103656A (en) 2000-04-28
IL130150A (en) 2004-09-27
US6444859B2 (en) 2002-09-03
JP2006137769A (ja) 2006-06-01
SK284243B6 (sk) 2004-12-01
KR20000070482A (ko) 2000-11-25
PT967975E (pt) 2001-11-30
CN1321958C (zh) 2007-06-20
JP2005279283A (ja) 2005-10-13
DK0967975T3 (da) 2001-09-17
ES2170474T3 (es) 2002-08-01
ATE320798T1 (de) 2006-04-15
BR9806996A (pt) 2000-03-14
US20060148906A1 (en) 2006-07-06
JP2001187729A (ja) 2001-07-10
CA2626424A1 (en) 1998-07-30
PL334477A1 (en) 2000-02-28
US6677492B2 (en) 2004-01-13
AR057610A2 (es) 2007-12-05
CN1560003A (zh) 2005-01-05
DK1114641T3 (da) 2006-05-15
US20040048932A1 (en) 2004-03-11
CN1244797A (zh) 2000-02-16
AU726733B2 (en) 2000-11-16
TR199901579T2 (xx) 1999-12-21
WO1998032430A1 (en) 1998-07-30
DE69833884T2 (de) 2006-08-24
ES2256104T3 (es) 2006-07-16
EP1114641A3 (en) 2003-05-28
EP1114641A2 (en) 2001-07-11
CN1899271A (zh) 2007-01-24
US5990176A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
CN1152674C (zh) 氟代醚组合物和抑制路易斯酸存在下其降解的方法
JP4253343B2 (ja) 麻酔用フルオロエーテル化合物の安定した医薬組成物、フルオロエーテル化合物の安定化方法、フルオロエーテル化合物の分解を防止するための安定剤の使用
CA2352597C (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
HK1074434B (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
CN1997360B (zh) 用于麻醉用途的氟代醚化合物的稳定的药物组合物,用于稳定氟代醚化合物的方法,稳定剂用于阻止氟代醚化合物降解的用途
MXPA99006919A (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
HK1108633B (en) Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ABBOTT PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: ABBOTT LAB

Effective date: 20100129

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20100129

Address after: Illinois, America

Co-patentee after: Central Glass Co., Ltd.

Patentee after: Abbott Laboratories

Address before: Illinois, America

Co-patentee before: Central Glass Co., Ltd.

Patentee before: Abbott company

CX01 Expiry of patent term

Granted publication date: 20040609

CX01 Expiry of patent term